AIM ImmunoTech Inc. last reported quarterly results on Aug 10, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $26,000 (+4.0% year over year) and diluted EPS of -$0.43. It usually reports 7–49 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 10, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Tuesday. Based on how many days after a quarter ends the company has reported recently. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 7–49 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 10, 2026
41 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
0
+4.0%
|
-4
-35.6%
|
-0.43
+88.3%
|
|
May 19, 2026
49 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
0
+37.5%
|
-3
+18.4%
|
-0.69
-1280.0%
|
|
Apr 16, 2020
16 days after quarter end
|
—
ended Mar 31, 2020
|
—
|
—
|
—
|
|
Oct 7, 2019
7 days after quarter end
|
—
ended Sep 30, 2019
|
—
|
—
|
—
|
|
Aug 15, 2017
46 days after quarter end
|
—
ended Jun 30, 2017
|
—
|
—
|
—
|
|
Apr 3, 2017
3 days after quarter end
|
—
ended Mar 31, 2017
|
—
|
—
|
—
|
|
Nov 15, 2016
46 days after quarter end
|
—
ended Sep 30, 2016
|
—
|
—
|
—
|
|
Aug 15, 2016
46 days after quarter end
|
—
ended Jun 30, 2016
|
—
|
—
|
—
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- AIM (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Ocala, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 946644
- Former names
- AIM ImmunoTech Inc. (until Nov 5, 2026); HEMISPHERX BIOPHARMA INC (until Aug 26, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.